# Innovent Biologics (Suzhou) Co. Ltd.: Phase 1 study closed enrollment, 30 enrolled (Hypertension)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of IBI3016 in People With Mild or Moderate Hypertension Patients |
| NCT ID | NCT07556796 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Hypertension |
| Intervention types | drug, other |
| Target enrollment | 30 |
| Site countries | China |
| Posted | 2026-04-29 |
| Planned start | 2026-05-08 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-23 |
| Last update posted | 2026-09-23 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07556796). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.